CL2014003605A1 - Proteínas de fusión de interleuquina-10 y usos de las mismas - Google Patents

Proteínas de fusión de interleuquina-10 y usos de las mismas

Info

Publication number
CL2014003605A1
CL2014003605A1 CL2014003605A CL2014003605A CL2014003605A1 CL 2014003605 A1 CL2014003605 A1 CL 2014003605A1 CL 2014003605 A CL2014003605 A CL 2014003605A CL 2014003605 A CL2014003605 A CL 2014003605A CL 2014003605 A1 CL2014003605 A1 CL 2014003605A1
Authority
CL
Chile
Prior art keywords
interleukin
fusion proteins
fusion
proteins
Prior art date
Application number
CL2014003605A
Other languages
English (en)
Inventor
Pablo Umana
Ralf Hosse
Jens Fischer
Lydia Jasmin Duerner
Thomas Emrich
Ekkhehard Moessner
Daigen Xu
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003605(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2014003605A1 publication Critical patent/CL2014003605A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2014003605A 2012-08-08 2014-12-31 Proteínas de fusión de interleuquina-10 y usos de las mismas CL2014003605A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12179709 2012-08-08

Publications (1)

Publication Number Publication Date
CL2014003605A1 true CL2014003605A1 (es) 2015-04-06

Family

ID=48917543

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003605A CL2014003605A1 (es) 2012-08-08 2014-12-31 Proteínas de fusión de interleuquina-10 y usos de las mismas

Country Status (22)

Country Link
US (2) US9346872B2 (es)
EP (1) EP2882774B1 (es)
JP (3) JP2015530983A (es)
KR (1) KR20150038012A (es)
CN (1) CN104540848B (es)
AR (1) AR092050A1 (es)
AU (1) AU2013301656A1 (es)
BR (1) BR112015002085A2 (es)
CA (1) CA2876285A1 (es)
CL (1) CL2014003605A1 (es)
CO (1) CO7151522A2 (es)
CR (1) CR20140565A (es)
EA (1) EA201500208A1 (es)
IL (1) IL236809A0 (es)
MA (1) MA20150232A1 (es)
MX (1) MX2015001675A (es)
PE (1) PE20150645A1 (es)
PH (1) PH12015500284A1 (es)
SG (1) SG11201408526SA (es)
TW (1) TW201418283A (es)
WO (1) WO2014023673A1 (es)
ZA (1) ZA201409304B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
MX2016005614A (es) 2013-11-01 2016-12-09 Spherium Biomed S L Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
EP3102594A1 (en) * 2014-02-06 2016-12-14 F. Hoffmann-La Roche AG Interleukine 10 immunoconjugates
JP6836500B2 (ja) 2014-05-16 2021-03-03 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 自己免疫状態および炎症状態を治療するための方法および組成物
TN2016000578A1 (en) 2014-07-30 2018-04-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
MX391388B (es) 2014-11-14 2025-03-21 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf.
WO2016100788A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
WO2017087768A1 (en) * 2015-11-18 2017-05-26 Duke University Targeted delivery of interleukin-10 to tumor infiltrating lymphocytes
AU2016362777B2 (en) * 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
CN108948207B (zh) * 2017-05-22 2020-11-13 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
EP3688036A4 (en) * 2017-09-25 2021-06-23 Dingfu Biotarget Co., Ltd PROTEINOUS HETERODIMER AND USE OF IT
WO2019057181A1 (en) * 2017-09-25 2019-03-28 Dingfu Biotarget Co., Ltd. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
TW202033766A (zh) * 2018-11-26 2020-09-16 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素１０變體及其衍生物
US11084857B2 (en) 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
US20220144911A1 (en) * 2019-02-01 2022-05-12 Uab Research Foundation Methods and compositions for il10 signaling antagonism
WO2020172631A2 (en) 2019-02-21 2020-08-27 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
CN121652287A (zh) 2019-03-06 2026-03-13 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
CN111909276A (zh) * 2019-05-10 2020-11-10 复旦大学 一种融合蛋白及其用途
US20230038502A1 (en) * 2019-06-11 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021006603A1 (ko) * 2019-07-08 2021-01-14 주식회사 프로젠 신규 알러지 질환 치료용 약학적 조성물
KR20210006301A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 융합단백질 및 그의 용도
US20220267396A1 (en) * 2019-07-08 2022-08-25 Progen Co., Ltd. Novel il-10 variant protein and use thereof
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7767290B2 (ja) 2020-01-11 2025-11-11 アスクジーン・ファーマ・インコーポレイテッド 新規なマスクされたサイトカインおよびその使用方法
KR20220139915A (ko) * 2020-02-06 2022-10-17 브리스톨-마이어스 스큅 컴퍼니 Il-10 및 그의 용도
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US11673930B2 (en) 2020-05-12 2023-06-13 Regeneran Pharmaceuticals, Inc. IL10 agonists and methods of use thereof
WO2021230705A1 (ko) * 2020-05-14 2021-11-18 주식회사 프로젠 신규 재조합 융합단백질 및 그의 용도
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4157460A1 (en) 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
TW202216744A (zh) * 2020-07-20 2022-05-01 美商維埃拉生物股份有限公司 用於治療自體免疫性病症和炎性病症之免疫細胞介素
EP4181957A4 (en) 2020-07-20 2024-08-07 Deka Biosciences, Inc. TWO-CYTOKINE FUSION PROTEIN COMPRISING IL-10
PY21108779A (es) * 2020-12-10 2022-08-11 Biocad Joint Stock Co Inmunocitoquina para activar el receptor il-10ra humano y su uso
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
KR20220099656A (ko) * 2021-01-07 2022-07-14 주식회사 프로젠 신규 il-10 변이체 융합단백질 생산용 세포주 및 그의 용도
US20240076331A1 (en) * 2021-02-01 2024-03-07 AskGene Pharma, Inc. Chimeric Molecules Comprising an IL-10 or TGF-Beta Agonist Polypeptide
CN119101170A (zh) * 2021-11-02 2024-12-10 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽
CN115960248A (zh) * 2022-07-08 2023-04-14 盛禾(中国)生物制药有限公司 一种二聚体融合蛋白及其应用
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
CN120476198A (zh) * 2023-01-03 2025-08-12 深圳市生葆生物科技有限公司 分泌白介素-10的细菌
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN121343001A (zh) * 2024-07-16 2026-01-16 广东菲鹏制药股份有限公司 一种融合蛋白及其用途
WO2026043909A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2026043906A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186567A (en) 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR20090008467A (ko) * 2006-05-08 2009-01-21 필로겐 에스.피.에이. 치료용의 항체­표적 사이토카인
SI2209805T1 (sl) * 2007-10-30 2017-11-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3102594A1 (en) 2014-02-06 2016-12-14 F. Hoffmann-La Roche AG Interleukine 10 immunoconjugates

Also Published As

Publication number Publication date
US20140044674A1 (en) 2014-02-13
PE20150645A1 (es) 2015-05-11
US10040843B2 (en) 2018-08-07
JP2015530983A (ja) 2015-10-29
JP2019033755A (ja) 2019-03-07
JP2021087426A (ja) 2021-06-10
EA201500208A1 (ru) 2015-07-30
CR20140565A (es) 2015-02-12
CN104540848B (zh) 2019-05-31
EP2882774B1 (en) 2018-10-03
AU2013301656A1 (en) 2015-01-15
US20160340413A1 (en) 2016-11-24
EP2882774A1 (en) 2015-06-17
MX2015001675A (es) 2015-04-10
HK1209439A1 (en) 2016-04-01
KR20150038012A (ko) 2015-04-08
CO7151522A2 (es) 2014-12-29
BR112015002085A2 (pt) 2017-12-19
CA2876285A1 (en) 2014-02-13
IL236809A0 (en) 2015-03-31
ZA201409304B (en) 2017-09-27
SG11201408526SA (en) 2015-03-30
AR092050A1 (es) 2015-03-18
TW201418283A (zh) 2014-05-16
JP6985232B2 (ja) 2021-12-22
WO2014023673A1 (en) 2014-02-13
PH12015500284A1 (en) 2015-04-27
US9346872B2 (en) 2016-05-24
MA20150232A1 (fr) 2015-07-31
CN104540848A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
IL286784A (en) Compositions of protein and antibody
IL236809A0 (en) Interleukin-10 fusion proteins and their use
CL2015001371A1 (es) Proteínas de fusión de enzima lisosomal terapéutica objetivo y usos de las mismas
IL236933A0 (en) Interleukin-2 fusion proteins and their use
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
PT3744835T (pt) Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas
BR112014000055A2 (pt) polipeptídeos de fusão de relaxina e usos dos mesmos
CO7071095A2 (es) Anticuerpos humanos anti-cd27, métodos, y usos
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
EP2970398A4 (en) RSV-F PREFUSION PROTEINS AND THEIR USE
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
DK3489254T3 (da) Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf
CL2016000981A1 (es) Formulaciones de estrigolactona y sus usos
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
BR112014019459A2 (pt) proteínas de ligação à cdim e usos das mesmas
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
DK3434775T3 (da) Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf
EP2877854A4 (en) FUSION PROTEINS AND METHOD THEREFOR
CL2014000927A1 (es) Proteinas naglu humana recombinante y usos de la misma
HRP20190434T1 (hr) Fuzijski protein
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
PL2928905T3 (pl) Sposób oczyszczania białek terapeutycznych
CL2016000219A1 (es) Proteinas de fusión terapéutica.
BR112015011111A2 (pt) proteína multifuncional e formulação farmacêutica
EP2545080A4 (en) NPP1 FUSION PROTEIN